Profile data is unavailable for this security.
About the company
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
- Revenue in USD (TTM)1.28m
- Net income in USD-86.11m
- Incorporated2021
- Employees48.00
- LocationSenti Biosciences Inc2 Corporate Drive, First FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 382-3281
- Fax+1 (302) 655-5049
- Websitehttps://www.sentibio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 12.94m | 12.00 | -- | 0.3709 | 5.57 | 0.809 | -1.60 | -1.60 | 1.21 | 1.33 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Nexgel Inc | 4.74m | -3.20m | 12.95m | 19.00 | -- | 2.71 | -- | 2.74 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Actavia Life Sciences Inc | 0.00 | -406.65k | 13.04m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
Dominari Holdings Inc | 3.41m | -24.56m | 13.12m | 26.00 | -- | 0.2752 | -- | 3.85 | -4.64 | -4.64 | 0.6305 | 8.03 | 0.0539 | -- | 0.8023 | 131,000.00 | -38.88 | -26.82 | -39.93 | -27.45 | -- | -- | -721.11 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
Inhibikase Therapeutics Inc | 195.98k | -19.20m | 13.28m | 8.00 | -- | 1.76 | -- | 67.75 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Cell MedX Corp | 70.00 | -96.91k | 13.38m | 0.00 | -- | -- | -- | 191,080.50 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.40m | 46.00 | -- | 0.5715 | -- | 0.3274 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Check Cap Ltd | 0.00 | -17.57m | 13.42m | 85.00 | -- | 0.5669 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
Imunon Inc | 0.00 | -18.85m | 13.54m | 33.00 | -- | 1.59 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 13.58m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Senti Biosciences Inc | 1.28m | -86.11m | 13.73m | 48.00 | -- | 0.2445 | -- | 10.77 | -1.93 | -1.44 | 0.0285 | 1.23 | 0.0097 | -- | 2.94 | 26,562.50 | -65.33 | -- | -71.42 | -- | -- | -- | -6,753.80 | -- | -- | -- | 0.0018 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
Edesa Biotech Inc | 0.00 | -7.25m | 13.93m | 16.00 | -- | 3.22 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 14.01m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Microbot Medical Inc | 0.00 | -10.26m | 14.40m | 22.00 | -- | 2.33 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
Holder | Shares | % Held |
---|---|---|
ARK Investment Management LLCas of 31 Mar 2024 | 1.63m | 3.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 707.05k | 1.55% |
Intel Corp. (Investment Management)as of 31 Mar 2024 | 595.67k | 1.30% |
Triatomic Management LPas of 31 Mar 2024 | 310.53k | 0.68% |
Geode Capital Management LLCas of 31 Mar 2024 | 245.59k | 0.54% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 145.00k | 0.32% |
Two Sigma Investments LPas of 31 Mar 2024 | 93.62k | 0.21% |
Citadel Securities LLCas of 31 Mar 2024 | 79.01k | 0.17% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 40.05k | 0.09% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 39.10k | 0.09% |